Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/18198
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Objetivos de Desenvolvimento Sustentável
03 Saúde e Bem-EstarColeções
Metadata
Mostrar registro completo
SAFETY PROFILE OF THE 9-VALENT HPV VACCINE: A COMBINED ANALYSIS OF 7 PHASE III CLINICAL TRIALS
Vacinas contra papilomavírus humano
Humanos
Infecção
Vacina quadrivalente
Human Papillomavirus Vaccines
Human
Infection
Quadrivalent vaccine
Autor(es)
Moreira Júnior, Edson Duarte
Block, Stan L
Ferris, Daron
Giuliano, Anna R
Iversen, Ole-Erik
Joura, Elmar A
Kosalaraksa, Pope
Schilling, Andrea
Van Damme, Pierre
Bornstein, Jacob
Bosch, F Xavier
Pils, Sophie
Cuzick, Jack
Garland, Suzanne M
Huh, Warner
Kjaer, Susanne K
Qi, Hong
Hyatt, Donna
Martin, Jason
Moeller, Erin
Ritter, Michael
Baudin, Martine
Luxembourg, Alain
Block, Stan L
Ferris, Daron
Giuliano, Anna R
Iversen, Ole-Erik
Joura, Elmar A
Kosalaraksa, Pope
Schilling, Andrea
Van Damme, Pierre
Bornstein, Jacob
Bosch, F Xavier
Pils, Sophie
Cuzick, Jack
Garland, Suzanne M
Huh, Warner
Kjaer, Susanne K
Qi, Hong
Hyatt, Donna
Martin, Jason
Moeller, Erin
Ritter, Michael
Baudin, Martine
Luxembourg, Alain
Afiliação
Associação Obras Sociais Irmã Dulce. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
Kentucky Pediatric Adult Research, Inc. Bardstown, Kentucky
Augusta University. Medical College of Georgia. Department of Medicine. Augusta, Georgia
Center for Infection Research in Cancer, Moffitt Cancer Center. Tampa, Florida
University of Bergen. Department of Gynaecology. Bergen, Norway
Medical University of Vienna. Department of Obstetrics. Vienna, Austria
Khon Kaen University. Department of Medicine. Khon Kaen, Thailand
Universidad Del Desarrollo. Facultad de Medicina Clínica Alemana. Departamento de Ginecología y Obstetricia Clínica Alemana. Santiago, Chile
University of Antwerp. Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute. Antwerp, Belgium
J University Faculty of Medicine. Department of Obstetrics and Gynecology. Galilee Medical Center and BarIlan. Nahariya, Israel
Catalan Institute of Oncology/ IDIBELL. Barcelona, Spain
Medical University of Vienna. Department of Obstetrics. Vienna, Austria
Wolfson Institute of Preventive Medicine. London, United Kingdom
University of Melbourne and Murdoch Childrens Research Institute. Royal Women’s Hospital. Parkville, Australia
University of Alabama Birmingham. Division of Gynecologic Oncology. Birmingham, Alabama
University of Copenhagen. Danish Cancer Society Research Center and Department of Gynecology, Rigshospitalet. Copenhagen, Denmark
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Kentucky Pediatric Adult Research, Inc. Bardstown, Kentucky
Augusta University. Medical College of Georgia. Department of Medicine. Augusta, Georgia
Center for Infection Research in Cancer, Moffitt Cancer Center. Tampa, Florida
University of Bergen. Department of Gynaecology. Bergen, Norway
Medical University of Vienna. Department of Obstetrics. Vienna, Austria
Khon Kaen University. Department of Medicine. Khon Kaen, Thailand
Universidad Del Desarrollo. Facultad de Medicina Clínica Alemana. Departamento de Ginecología y Obstetricia Clínica Alemana. Santiago, Chile
University of Antwerp. Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute. Antwerp, Belgium
J University Faculty of Medicine. Department of Obstetrics and Gynecology. Galilee Medical Center and BarIlan. Nahariya, Israel
Catalan Institute of Oncology/ IDIBELL. Barcelona, Spain
Medical University of Vienna. Department of Obstetrics. Vienna, Austria
Wolfson Institute of Preventive Medicine. London, United Kingdom
University of Melbourne and Murdoch Childrens Research Institute. Royal Women’s Hospital. Parkville, Australia
University of Alabama Birmingham. Division of Gynecologic Oncology. Birmingham, Alabama
University of Copenhagen. Danish Cancer Society Research Center and Department of Gynecology, Rigshospitalet. Copenhagen, Denmark
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Merck & Co., Inc. Kenilworth, New Jersey
Resumo em Inglês
The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at entry), 9 to 26 years of age. OBJECTIVES: The overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine abstract
was evaluated across 7 Phase III studies, conducted in males and females (nonpregnant at
entry), 9 to 26 years of age.
METHODS: Vaccination was administered as a 3-dose regimen at day 1, and months 2 and 6.
More than 15 000 subjects received ≥1 dose of 9vHPV vaccine. In 2 of the studies, >7000
control subjects received ≥1 dose of quadrivalent HPV (qHPV) vaccine. Serious and
nonserious adverse events (AEs) and new medical conditions were recorded throughout
the study. Subjects testing positive for pregnancy at day 1 were not vaccinated; those who
became pregnant after day 1 were discontinued from further vaccination until resolution of
the pregnancy. Pregnancies detected after study start (n = 2950) were followed to outcome.
RESULTS: The most common AEs (≥5%) experienced by 9vHPV vaccine recipients were
injection-site AEs (pain, swelling, erythema) and vaccine-related systemic AEs (headache,
pyrexia). Injection-site AEs were more common in 9vHPV vaccine than qHPV vaccine
recipients; most were mild-to-moderate in intensity. Discontinuations and vaccine-related
serious AEs were rare (0.1% and <0.1%, respectively). Seven deaths were reported; none
were considered vaccine related. The proportions of pregnancies with adverse outcome
were within ranges reported in the general population.
CONCLUSIONS: The 9vHPV vaccine was generally well tolerated in subjects aged 9 to 26
years with an AE profile similar to that of the qHPV vaccine; injection-site AEs were more
common with 9vHPV vaccine. Its additional coverage and safety profile support widespread
9vHPV vaccination.
Palavras-chave
Vacinas contra HPVVacinas contra papilomavírus humano
Humanos
Infecção
Vacina quadrivalente
Palavras-chave em inglês
HPV vaccinesHuman Papillomavirus Vaccines
Human
Infection
Quadrivalent vaccine
Compartilhar